Cynata Therapeutics (CYP) Q1 2026 TU earnings summary

Executive summary

• Two major clinical trial readouts (Phase 3 osteoarthritis, Phase 2 aGvHD) expected in Q2 CY 2026, marking a pivotal period for the company.

• Continued progress in three key clinical trials: osteoarthritis, aGvHD, and kidney transplantation, with final patient visits and enrolment nearing completion.

• Positioned as a leader in scalable MSC manufacturing, enabling off-the-shelf therapies and licensing opportunities.

• No material safety concerns identified with MSC-based therapies to date.

• Ongoing efforts to strengthen relationships with key opinion leaders, partners, and investors.

Financial highlights

• Cash balance at quarter end was $3.166 million (AUD 3.2 million), with an additional ~$1.7 million R&D Tax Incentive rebate expected or received, totaling ~$4.9 million.

• Net operating cash outflows for the quarter were $1.883 million, down 45% from the previous quarter.

• Standby capital facility of $7.5 million (AUD 7.5 million) established with Acuity Capital, providing funding flexibility through July 2030.

• Cash runway extends through mid-2026, covering the period until after trial readouts.

Outlook and guidance

• Results from both major clinical trials expected in Q2 CY 2026, representing key milestones for future commercial opportunities.

• Preliminary results for Cohort 1 of the kidney transplantation trial expected in Q4 CY 2025.

• Anticipation of increased partnering, licensing, or M&A activity following trial results.

• Focus on securing commercial partnerships to fund further development and commercialization.